23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
May 26, 2022 16:05 ET
|
23andMe Holding Co.
Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services...
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
May 12, 2022 16:10 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 15, 2022 06:45 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access,...
23andMe to Present at Cowen 42nd Annual Health Care Conference
February 25, 2022 08:30 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand,...
23andMe to Present at Citi’s 2022 Virtual Healthcare Conference
February 17, 2022 09:00 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand,...
23andMe Reports FY2022 Third Quarter Financial Results
February 10, 2022 16:04 ET
|
23andMe Holding Co.
Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of...
23andMe to Report FY2022 Third Quarter Financial Results
January 27, 2022 16:05 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
January 18, 2022 06:55 ET
|
23andMe Holding Co.
GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe...
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
January 10, 2022 08:00 ET
|
23andMe Holding Co.
SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health...
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
January 06, 2022 09:00 ET
|
23andMe Holding Co.
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey...